Revol-Cavalier J, Quaranta A, Newman J, Brash A, Hamberg M, Wheelock C
Chem Rev. 2024; 125(1):1-90.
PMID: 39680864
PMC: 11719350.
DOI: 10.1021/acs.chemrev.3c00520.
Lankin V, Tikhaze A, Sharapov M, Konovalova G
Rev Cardiovasc Med. 2024; 25(8):295.
PMID: 39228481
PMC: 11367011.
DOI: 10.31083/j.rcm2508295.
Wang C, Kaufmann A, Kampschulte N, Elbelt U, Kassner U, Steinhagen-Thiessen E
Atheroscler Plus. 2024; 55:55-62.
PMID: 38390468
PMC: 10881432.
DOI: 10.1016/j.athplu.2024.01.005.
Lankin V, Tikhaze A, Melkumyants A
Antioxidants (Basel). 2022; 11(8).
PMID: 36009284
PMC: 9405452.
DOI: 10.3390/antiox11081565.
Snodgrass R, Brune B
Front Pharmacol. 2019; 10:719.
PMID: 31333453
PMC: 6620526.
DOI: 10.3389/fphar.2019.00719.
Biological and pathophysiological roles of end-products of DHA oxidation.
Yakubenko V, Byzova T
Biochim Biophys Acta Mol Cell Biol Lipids. 2016; 1862(4):407-415.
PMID: 27713004
PMC: 5360178.
DOI: 10.1016/j.bbalip.2016.09.022.
Hydroxyoctadecadienoic acids regulate apoptosis in human THP-1 cells in a PPARγ-dependent manner.
Vangaveti V, Shashidhar V, Rush C, Malabu U, Rasalam R, Collier F
Lipids. 2014; 49(12):1181-92.
PMID: 25330944
DOI: 10.1007/s11745-014-3954-z.
Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis.
Ramsden C, Zamora D, Leelarthaepin B, Majchrzak-Hong S, Faurot K, Suchindran C
BMJ. 2013; 346:e8707.
PMID: 23386268
PMC: 4688426.
DOI: 10.1136/bmj.e8707.
Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis.
Vangaveti V, Baune B, Kennedy R
Ther Adv Endocrinol Metab. 2012; 1(2):51-60.
PMID: 23148150
PMC: 3475286.
DOI: 10.1177/2042018810375656.
Physiological antioxidative network of the bilirubin system in aging and age-related diseases.
Kim S, Park S
Front Pharmacol. 2012; 3:45.
PMID: 22457648
PMC: 3303147.
DOI: 10.3389/fphar.2012.00045.
Electrospray MS/MS reveals extensive and nonspecific oxidation of cholesterol esters in human peripheral vascular lesions.
Hutchins P, Moore E, Murphy R
J Lipid Res. 2011; 52(11):2070-83.
PMID: 21885431
PMC: 3196238.
DOI: 10.1194/jlr.M019174.
Postprandial lipid oxidation and cardiovascular disease risk.
Bowen P, Borthakur G
Curr Atheroscler Rep. 2004; 6(6):477-84.
PMID: 15485594
DOI: 10.1007/s11883-004-0089-3.
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin V, Tikhaze A, Kukharchuk V, Konovalova G, Pisarenko O, Kaminnyi A
Mol Cell Biochem. 2003; 249(1-2):129-40.
PMID: 12956408
The content of lipoperoxidation products in normal and atherosclerotic human aorta.
Tertov V, Kaplun V, Mikhailova I, Suprun I, Orekhov A
Mol Cell Biochem. 2001; 225(1-):21-8.
PMID: 11716360
DOI: 10.1023/a:1012267520932.
Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions.
Napoli C, DArmiento F, Mancini F, Postiglione A, Witztum J, Palumbo G
J Clin Invest. 1998; 100(11):2680-90.
PMID: 9389731
PMC: 508471.
DOI: 10.1172/JCI119813.
In vivo action of 15-lipoxygenase in early stages of human atherogenesis.
Kuhn H, Heydeck D, Hugou I, Gniwotta C
J Clin Invest. 1997; 99(5):888-93.
PMID: 9062346
PMC: 507896.
DOI: 10.1172/JCI119253.
Lipoxygenase treatment render low-density lipoprotein susceptible to Cu2+-catalysed oxidation.
Lass A, Belkner J, Esterbauer H, Kuhn H
Biochem J. 1996; 314 ( Pt 2):577-85.
PMID: 8670073
PMC: 1217088.
DOI: 10.1042/bj3140577.
Lipoproteins and their functions.
Habenicht A, Ziegler R, Schettler G
Clin Investig. 1994; 72(9):639-52.
PMID: 7849441
DOI: 10.1007/BF00212981.
Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques.
Folcik V, Krajewski L, Cathcart M
J Clin Invest. 1995; 96(1):504-10.
PMID: 7615823
PMC: 185224.
DOI: 10.1172/JCI118062.